A conversation featuring Ruth Lehmann and Kevin B. Churchwell, MD, the President and Chief Executive Officer of Boston Children’s Hospital and a member of the Whitehead Institute Board of Directors.
In this webinar, Whitehead Fellow Tobi Oni outlines the general principles of anti-tumor immune responses and discusses his lab's strategies to unleash an immune attack against pancreatic cancer.
The challenges presented by climate change are wide-ranging — and so must be science's response. In this Director’s Dialogue, which took place on May 4, 2021, three Whitehead Institute scientists, Jing-Ke Weng, Mary Gehring and Jonathan Weissman, speak with Institute Director Ruth Lehmann about exciting opportunities for leveraging fundamental biological research to create biotechnologies that address some of climate change's vexing effects.
In this webinar, which took place April 8, 2021, Whitehead Institute Member Yukiko Yamashita highlights ways in which fundamental research brings novel biological processes to light, and introduces her lab’s latest discoveries on the function of satellite DNA, which has long been regarded as “genomic junk.”
On March 22, Whitehead Institute Director Ruth Lehmann spoke with Moderna chairman and founder and CEO of life sciences venture capital company Flagship Pioneering Noubar Afeyan about the race to create a COVID-19 vaccine, the importance of immigrants in the US, and how to find and foster path-breaking ideas.
On February 25, 2021, Whitehead Institute Director Ruth Lehmann discussed the implications of this new age MIT President Emerita Susan Hockfield, in the first installment of our new series, Director's Dialogues. Hockfield, who was the first life scientist to lead MIT, is the author of the 2019 book, “The Age of Living Machines: How Biology Will Build the Next Technology Revolution.”
In this presentation and discussion moderated by Whitehead Institute Member Pulin Li, hear what Whitehead Fellows Silvia Rouskin and Kipp Weiskopf are learning about SARS-CoV-2 — and how their research may aid in the fight against dangerous coronaviruses, now and well into the future.
In this talk from May 27, 2021, Whitehead Institute Director Ruth Lehmann talks to biomedical researcher, MIT professor, and biotech entrepreneur Sangeeta Bhatia. Bhatia leverages ‘tiny technologies’ of miniaturization to yield inventions such as human microlivers that model human drug metabolism and liver disease, as well as responsive nanoparticles and nanoporous materials that can be engineered to diagnose, study, and treat a variety of diseases, including cancer.